Regeneron Pharmaceuticals
REGNHealth careStock · Data from SEC EDGAR 13F · Held by 12 of 87 tracked investors
Regeneron Pharmaceuticals at a glance
An overview of the financial statements, in plain language. Switch to the advanced view for charts.
- Valuation70
- Growth65
- Profitability93
- Quality79
- Debt100
- Stability94
Chart REGN
Insider purchases
last 90 days, SEC Form 4Which investors hold this stock
12MH Mason Hawkins Southeastern Asset Management | 4.95% |
CA Cliff Asness AQR Capital Management | 0.24% |
JG Joel Greenblatt Gotham Asset Management | 0.15% |
RD Ray Dalio Bridgewater Associates | 0.13% |
JS Jim Simons Renaissance Technologies | 0.13% |
Čn Česká národní banka Česká národní banka | 0.11% |
Šn Švýcarská národní banka Swiss National Bank | 0.1% |
Ns Norský státní fond Norges Bank | 0.07% |
GI Generali Investments CEE Generali Investments CEE | 0.07% |
IE Israel Englander Millennium Management | 0.04% |
JY Jeff Yass Susquehanna International Group | 0.01% |
MG Mario Gabelli GAMCO Investors | 0% |
Frequently asked questions
How much is Regeneron Pharmaceuticals (REGN) stock?
Regeneron Pharmaceuticals shares trade at $805.02, -1.72% over the last trading day. The price is delayed.
What is the market cap of Regeneron Pharmaceuticals?
The market cap of Regeneron Pharmaceuticals is about $82.9B and its price-to-earnings ratio (P/E) is 19.9.
Does Regeneron Pharmaceuticals pay a dividend?
The dividend yield of Regeneron Pharmaceuticals is 0.46% a year. The yield can change with the company's decisions.
How has Regeneron Pharmaceuticals stock performed over the last year?
The Regeneron Pharmaceuticals share price changed by +39.29% over 12 months and by +25.80% over 5 years.
Which big investors hold Regeneron Pharmaceuticals?
According to the latest 13F filings, 12 of 87 tracked investors hold Regeneron Pharmaceuticals, for example Mason Hawkins, Cliff Asness, Joel Greenblatt.
When will Regeneron Pharmaceuticals report its next results?
The next earnings report of Regeneron Pharmaceuticals is expected on 30 Oct 2026.
Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.